Picture EBD Group World of Partnering Opportunities 650x100px

Product › Details

Nanobodies® (Ablynx)

	Next higher product group	antibody
	Status	2005-09-01 development existent
	Organisation	Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)
	Group	Sanofi (Group) [since May 2011]
	Original research	Vrije Universiteit Brussel (VUB)

Record changed: 2023-07-10

Picture Berlin Partner Special Topic HealthCapital Berlin-Brandenburg 650x200px

More documents for Nanobodies® (Ablynx)

[1] MoonLake Immunotherapeutics AG. (6/28/23). "Press Release: MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares". Zug....
[2] MoonLake Immunotherapeutics AG. (6/26/23). "Press Release: MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering". Zug....
[3] MoonLake Immunotherapeutics AG. (6/25/23). "Press Release: MoonLake Immunotherapeutics Achieves Landmark Milestone with Positive Phase 2 Results for Nanobody Sonelokimab in Hidradenitis Suppurativa". Zug....
[4] MoonLake Immunotherapeutics AG. (10/4/21). "Press Release: MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody Sonelokimab". Zu...
[5] MoonLake Immunotherapeutics AG. (8/10/21). "Press Release: MoonLake Immunotherapeutics Appoints Former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors". Zug....
[6] MoonLake Immunotherapeutics AG. (7/1/21). "Press Release: MoonLake Immunotherapeutics Appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO". Zug....
[7] MoonLake Immunotherapeutics AG. (5/6/21). "Press Release: MoonLake Immunotherapeutics Announces Publication in The Lancet". Zug....
[8] MoonLake Immunotherapeutics AG. (5/3/21). "Press Release: MoonLake In-licensing and Launch". Zug....
[9] Merck KGaA. (10/6/20). "Press Release: Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis [Not intended for UK and US based media]". Darmstadt....
[10] Sanofi S.A.. (2/6/19). "Press Release: FDA Approves Cablivi (caplacizumab-yhdp), the First Nanobody-based Medicine, for Adults with Acquired Thrombotic Thrombocytopenic Purpura (aTTP)". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]